RECRUITING

Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Investigators hypothesize that topical tranexamic acid will have better or comparable efficacy to topical thrombin in reducing hematoma formation at the wound base. The purpose of the study is to demonstrate that topical tranexamic acid will be a non-inferior alternative medication to the current standard of care,THROMBIN-JMI® , and at a lower cost to the health system.

Official Title

The Use of Topical Tranexamic Acid Versus Thrombin Spray for the Management of Split Thickness Skin Graft Recipient Site in Burn Management

Quick Facts

Study Start:2024-07-11
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06379724

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * English or Spanish speaking
  2. * Flame or scald burn injury
  3. * \<=10% total body surface area (TBSA) partial thickness
  4. * \<= 5% total body surface area (TBSA) deep partial or full thickness
  5. * Skin graft harvested at 1/12 inch depth, meshed 1:1 or pie crusted if the area is a small functional area
  1. * \>10% total body surface area (TBSA) partial thickness burn
  2. * \>5% total body surface area (TBSA )surgical area of burn injury (deep partial or full thickness injury)
  3. * Traumatic or chemical burn mechanism
  4. * Patients on immunosuppression
  5. * Uncontrolled diabetes
  6. * Known diagnosis of peripheral vascular disease or diagnosis at time of injury
  7. * Pregnant women
  8. * Patients with acquired defective color vision
  9. * Patients with subarachnoid hemorrhage
  10. * Patients with active intravascular clotting or known hypersensitivity reactions to tranexamic acid
  11. * Inability to give informed consent

Contacts and Locations

Study Contact

Jessica Reynolds, BSN
CONTACT
913-588-5000
jreynolds11@kumc.edu

Principal Investigator

Dhaval Bhavsar, MBBS
PRINCIPAL_INVESTIGATOR
The University of Kansas Medical Center

Study Locations (Sites)

The University of Kansas Health System
Kansas City, Kansas, 66160
United States

Collaborators and Investigators

Sponsor: University of Kansas Medical Center

  • Dhaval Bhavsar, MBBS, PRINCIPAL_INVESTIGATOR, The University of Kansas Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-11
Study Completion Date2026-12

Study Record Updates

Study Start Date2024-07-11
Study Completion Date2026-12

Terms related to this study

Additional Relevant MeSH Terms

  • Burns
  • Skin Graft Complications